{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:03:38Z","timestamp":1790676218377,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006800","name":"Honorable Tina Brozman Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006800","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001036","name":"Claneil Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.pharmthera.2020.107524","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:52:18Z","timestamp":1584492738000},"page":"107524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The tubal epigenome \u2013 An emerging target for ovarian cancer"],"prefix":"10.1016","volume":"210","author":[{"given":"Hunter D.","family":"Reavis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Drapkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2020.107524_bb0005","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: Strategies for overcoming resistance to chemotherapy","volume":"3","author":"Agarwal","year":"2003","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0010","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study group","volume":"30","author":"Alsop","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0015","doi-asserted-by":"crossref","first-page":"a019521","DOI":"10.1101\/cshperspect.a019521","article-title":"Histone modifications and cancer","volume":"8","author":"Audia","year":"2016","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0020","first-page":"5329","article-title":"BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study","volume":"60","author":"Baldwin","year":"2000","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0025","doi-asserted-by":"crossref","first-page":"11620","DOI":"10.1038\/ncomms11620","article-title":"Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution","volume":"7","author":"Bartlett","year":"2016","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0030","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.canlet.2009.03.013","article-title":"Histone deacetylase inhibitors as anti-neoplastic agents","volume":"280","author":"Batty","year":"2009","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0035","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1146\/annurev-pharmtox-010716-105106","article-title":"Targeting epigenetics in cancer","volume":"58","author":"Bennett","year":"2018","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0045","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ncb3582","article-title":"ARID1A-mutated ovarian cancers depend on HDAC6 activity","volume":"19","author":"Bitler","year":"2017","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0050","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research, N","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0055","series-title":"Ovarian cancer","author":"Cancer Statistics Center","year":"2019"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0060","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/PGP.0b013e3181c713a8","article-title":"Serous tubal intraepithelial carcinoma: Diagnostic reproducibility and its implications","volume":"29","author":"Carlson","year":"2010","journal-title":"International Journal of Gynecological Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0065","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0070","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cell.2013.06.005","article-title":"Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity","volume":"154","author":"Chaffer","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0075","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1038\/s41467-019-11862-x","article-title":"The molecular origin and taxonomy of mucinous ovarian carcinoma","volume":"10","author":"Cheasley","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0080","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/1471-0528.14543","article-title":"Serous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: A systematic review","volume":"124","author":"Chen","year":"2017","journal-title":"BJOG"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0085","doi-asserted-by":"crossref","first-page":"188312","DOI":"10.1016\/j.bbcan.2019.188312","article-title":"Functional analysis of deubiquitylating enzymes in tumorigenesis and development","volume":"1872","author":"Cheng","year":"2019","journal-title":"Biochimica Et Biophysica Acta. Reviews on Cancer"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0090","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.celrep.2015.12.046","article-title":"Platinum and PARP inhibitor resistance due to overexpression of MicroRNA-622 in BRCA1-mutant Ovarian Cancer","volume":"14","author":"Choi","year":"2016","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0095","doi-asserted-by":"crossref","DOI":"10.1126\/science.aav1898","article-title":"The chromatin accessibility landscape of primary human cancers","volume":"362","author":"Corces","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0100","series-title":"Diagnostic gynecologic and obstetric pathology","first-page":"1","author":"Crum","year":"2017"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: From mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0110","first-page":"5460","article-title":"The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20\/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer","volume":"25","author":"Dickson","year":"2016","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0115","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1200\/JCO.19.00363","article-title":"Update on genetic testing in gynecologic cancer","volume":"37","author":"Domchek","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0120","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41467-017-01217-9","article-title":"Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma","volume":"8","author":"Ducie","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0125","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/2159-8290.CD-16-0607","article-title":"Genomics of Ovarian cancer progression reveals diverse metastatic trajectories including intraepithelial metastasis to the fallopian tube","volume":"6","author":"Eckert","year":"2016","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0130","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1038\/sj.onc.1205651","article-title":"DNA methylation in cancer: Too much, but also too little","volume":"21","author":"Ehrlich","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0135","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/path.5161","article-title":"Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors","volume":"246","author":"Elias","year":"2018","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0140","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","article-title":"Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors","volume":"92","author":"Esteller","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0145","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1158\/0008-5472.CAN-17-1492","article-title":"Genomic and Epigenomic signatures in Ovarian Cancer associated with Resensitization to platinum drugs","volume":"78","author":"Fang","year":"2018","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0150","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0140-6736(71)92335-X","article-title":"Incessant ovulation--a factor in ovarian neoplasia?","volume":"2","author":"Fathalla","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0155","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nature11979","article-title":"Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche","volume":"495","author":"Flesken-Nikitin","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0160","doi-asserted-by":"crossref","first-page":"l1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Science Signaling"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0165","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrd.2017.152","article-title":"Deubiquitylating enzymes and drug discovery: Emerging opportunities","volume":"17","author":"Harrigan","year":"2018","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0175","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1158\/0008-5472.CAN-18-2297","article-title":"Early loss of histone H2B Monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of Ovarian cancer","volume":"79","author":"Hooda","year":"2019","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0180","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1158\/0008-5472.CAN-04-1529","article-title":"Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients","volume":"64","author":"Ibanez de Caceres","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0185","series-title":"World cancer report","author":"International Agency for Research on Cancer, World Health Organization","year":"2014"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0190","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrg.2016.93","article-title":"Targeting the cancer epigenome for therapy","volume":"17","author":"Jones","year":"2016","journal-title":"Nature Reviews. Genetics"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0195","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41467-018-03031-3","article-title":"CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity","volume":"9","author":"Karakashev","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0200","doi-asserted-by":"crossref","first-page":"932371","DOI":"10.1155\/2010\/932371","article-title":"Ovarian cancer pathogenesis: A model in evolution","volume":"2010","author":"Karst","year":"2010","journal-title":"Journal of Oncology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0205","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","article-title":"Targeting the ATR\/CHK1 Axis with PARP inhibition results in tumor regression in BRCA-mutant Ovarian cancer models","volume":"23","author":"Kim","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0210","first-page":"166","article-title":"Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"American Journal of Translational Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0215","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1073\/pnas.1117135109","article-title":"High-grade serous ovarian cancer arises from fallopian tube in a mouse model","volume":"109","author":"Kim","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0220","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship","volume":"31","author":"Kindelberger","year":"2007","journal-title":"The American Journal of Surgical Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0225","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1158\/1541-7786.MCR-16-0097","article-title":"DNA Methylome analyses implicate fallopian tube epithelia as the origin for high-grade serous Ovarian cancer","volume":"14","author":"Klinkebiel","year":"2016","journal-title":"Molecular Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0230","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/GCO.0000000000000340","article-title":"Pathogenesis and heterogeneity of ovarian cancer","volume":"29","author":"Kroeger","year":"2017","journal-title":"Current Opinion in Obstetrics & Gynecology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0235","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The dualistic model of Ovarian carcinogenesis: Revisited, revised, and expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0240","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0245","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1470-2045(19)30019-1","article-title":"Extending the scope of PARP inhibitors in ovarian cancer","volume":"20","author":"Ledermann","year":"2019","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0250","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41586-019-1004-y","article-title":"Hepatocytes direct the formation of a pro-metastatic niche in the liver","volume":"567","author":"Lee","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0255","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee","year":"2007","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0260","first-page":"280","article-title":"Epithelial ovarian cancer: Evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0265","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0270","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/PGP.0b013e318264ae09","article-title":"Do deeper sections increase the frequency of detection of serous tubal intraepithelial carcinoma (STIC) in the \u201csectioning and extensively examining the FIMbriated end\u201d (SEE-FIM) protocol?","volume":"32","author":"Mahe","year":"2013","journal-title":"International Journal of Gynecological Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0275","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-11-3909","article-title":"Epigenetic resensitization to platinum in ovarian cancer","volume":"72","author":"Matei","year":"2012","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0280","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1158\/0008-5472.CAN-19-2558","article-title":"Murine Oviductal high-grade serous carcinomas Mirror the genomic alterations, gene expression profiles, and immune microenvironment of their human counterparts","volume":"80","author":"McCool","year":"2020","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0285","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamaoncol.2015.1618","article-title":"Next-generation sequencing of tubal intraepithelial carcinomas","volume":"1","author":"McDaniel","year":"2015","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0290","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"The American Journal of Surgical Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0295","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.celrep.2018.03.038","article-title":"Multifaceted impact of MicroRNA 493-5p on Genome-stabilizing pathways induces platinum and PARP inhibitor resistance in BRCA2-mutated carcinomas","volume":"23","author":"Meghani","year":"2018","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0300","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ygyno.2012.06.015","article-title":"Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls","volume":"127","author":"Mingels","year":"2012","journal-title":"Gynecologic Oncology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0305","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/annonc\/mdy174","article-title":"Latest clinical evidence and further development of PARP inhibitors in ovarian cancer","volume":"29","author":"Mirza","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0310","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/path.4663","article-title":"Genetically-defined ovarian cancer mouse models","volume":"238","author":"Morin","year":"2016","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0315","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1158\/1078-0432.CCR-19-0448","article-title":"The CHK1 inhibitor Prexasertib exhibits monotherapy activity in high-grade serous Ovarian cancer models and sensitizes to PARP inhibition","volume":"25","author":"Parmar","year":"2019","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0320","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0325","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","article-title":"Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models","volume":"24","author":"Perets","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0330","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0335","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0340","doi-asserted-by":"crossref","first-page":"6536","DOI":"10.1158\/1078-0432.CCR-18-1199","article-title":"Methylomic analysis of Ovarian cancers identifies tumor-specific alterations readily detectable in early precursor lesions","volume":"24","author":"Pisanic","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0345","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5483\/BMBRep.2019.52.3.048","article-title":"Deubiquitinating enzymes as cancer biomarkers: New therapeutic opportunities?","volume":"52","author":"Poondla","year":"2019","journal-title":"BMB Reports"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0350","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/PAS.0000000000000199","article-title":"Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery","volume":"38","author":"Rabban","year":"2014","journal-title":"The American Journal of Surgical Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0355","doi-asserted-by":"crossref","first-page":"349","DOI":"10.18632\/oncoscience.484","article-title":"H2Bub1: Guardian of chromatin accessibility in ovarian cancer","volume":"6","author":"Reavis","year":"2019","journal-title":"Oncoscience"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0360","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.cell.2016.07.050","article-title":"Epigenetic mechanisms of longevity and aging","volume":"166","author":"Sen","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0365","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/modpathol.2009.89","article-title":"Candidate serous cancer precursors in fallopian tube epithelium of BRCA1\/2 mutation carriers","volume":"22","author":"Shaw","year":"2009","journal-title":"Modern Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0370","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1101\/gad.1703008","article-title":"The histone H2B-specific ubiquitin ligase RNF20\/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression","volume":"22","author":"Shema","year":"2008","journal-title":"Genes & Development"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0375","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.4353","article-title":"A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development","volume":"233","author":"Sherman-Baust","year":"2014","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10120468","article-title":"Back to the future? The fallopian tube, Precursor escape and a dualistic model of high-grade serous carcinogenesis","volume":"10","author":"Soong","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0385","first-page":"E10981","article-title":"Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden","volume":"114","author":"Stone","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0390","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/path.5065","article-title":"Precious GEMMs: Emergence of faithful models for ovarian cancer research","volume":"245","author":"Stuckelberger","year":"2018","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0395","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): An international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0400","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/nm.3336","article-title":"The epigenetics of epithelial-mesenchymal plasticity in cancer","volume":"19","author":"Tam","year":"2013","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0405","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.celrep.2016.01.020","article-title":"RNF20 links histone H2B Ubiquitylation with inflammation and inflammation-associated cancer","volume":"14","author":"Tarcic","year":"2016","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0410","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw148","article-title":"Mechanisms of therapy resistance in patient-derived Xenograft models of BRCA1-deficient breast cancer","volume":"108","author":"Ter Brugge","year":"2016","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0415","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1158\/0008-5472.CAN-18-4018","article-title":"DFMO and 5-Azacytidine increase M1 macrophages in the tumor microenvironment of murine Ovarian cancer","volume":"79","author":"Travers","year":"2019","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0420","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/cr.2011.24","article-title":"Cancer epigenetics: Linking basic biology to clinical medicine","volume":"21","author":"Tsai","year":"2011","journal-title":"Cell Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0425","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/1078-0432.CCR-17-1958","article-title":"Epigenetic reprogramming strategies to reverse global loss of 5-Hydroxymethylcytosine, a prognostic factor for poor survival in high-grade serous Ovarian Cancer","volume":"24","author":"Tucker","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0430","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41416-019-0654-8","article-title":"Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers","volume":"122","author":"Tuna","year":"2020","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0435","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41556-018-0258-1","article-title":"Chromatin regulatory mechanisms and therapeutic opportunities in cancer","volume":"21","author":"Valencia","year":"2019","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0440","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/PGP.0000000000000207","article-title":"Molecular alterations of TP53 are a defining feature of Ovarian high-grade serous carcinoma: A rereview of cases lacking TP53 mutations in the cancer Genome Atlas Ovarian study","volume":"35","author":"Vang","year":"2016","journal-title":"International Journal of Gynecological Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0445","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/PGP.0b013e31823b8831","article-title":"Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma","volume":"31","author":"Vang","year":"2012","journal-title":"International Journal of Gynecological Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0450","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: Recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0455","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1097\/PAS.0b013e31822f58bc","article-title":"Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: A reproducibility study","volume":"35","author":"Visvanathan","year":"2011","journal-title":"The American Journal of Surgical Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0460","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2326-6066.CIR-15-0073","article-title":"Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine Ovarian cancer model","volume":"3","author":"Wang","year":"2015","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0465","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/IGC.0b013e3182a80ac8","article-title":"Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC)","volume":"23","author":"Wethington","year":"2013","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0470","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1158\/0008-5472.CAN-04-0238","article-title":"DNA hypomethylation and ovarian cancer biology","volume":"64","author":"Widschwendter","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0475","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1158\/1078-0432.CCR-07-5279","article-title":"Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer","volume":"14","author":"Woloszynska-Read","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0480","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/path.4783","article-title":"Impact of oviductal versus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse","volume":"240","author":"Wu","year":"2016","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0485","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5219","article-title":"Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions","volume":"248","author":"Wu","year":"2019","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0490","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1101\/gad.290957.116","article-title":"ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells","volume":"31","author":"Yazinski","year":"2017","journal-title":"Genes & Development"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0495","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030445","article-title":"Prostate cancer epigenetics: From basic mechanisms to clinical implications","volume":"9","author":"Yegnasubramanian","year":"2019","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0500","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/path.4927","article-title":"High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease","volume":"243","author":"Zhai","year":"2017","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0505","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1038\/s41467-019-13116-2","article-title":"Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma","volume":"10","author":"Zhang","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0510","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13059-019-1870-5","article-title":"Epigenetic modifications of histones in cancer","volume":"20","author":"Zhao","year":"2019","journal-title":"Genome Biology"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0515","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41586-018-0291-z","article-title":"CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions","volume":"559","author":"Zimmermann","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107524_bb0520","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1006\/gyno.1999.5623","article-title":"Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations","volume":"76","author":"Zweemer","year":"2000","journal-title":"Gynecologic Oncology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820300528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820300528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:09:11Z","timestamp":1759010951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725820300528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":104,"alternative-id":["S0163725820300528"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107524","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The tubal epigenome \u2013 An emerging target for ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107524"}}